Results of rhabdomyosarcoma treatment in a developing country


Karakas Z. , Agaoglu L., Biner B., Devecioglu O. , Anak S., Yalman N., ...More

ACTA MEDICA OKAYAMA, vol.54, no.4, pp.173-177, 2000 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 54 Issue: 4
  • Publication Date: 2000
  • Title of Journal : ACTA MEDICA OKAYAMA
  • Page Numbers: pp.173-177
  • Keywords: rhabdomyosarcoma, pediatric oncology, chemotherapy, SOFT-TISSUE SARCOMA, INTERGROUP RHABDOMYOSARCOMA, CHILDHOOD-CANCER, BIOLOGY

Abstract

Fifty-one children (median age: 4.5 years; 4 months-16 years) diagnosed with rhabdomyosarcoma were treated in our center between 1980-1999. The primary sites were head and neck in 31.4%, the genito-urinary system in 21.6%, and extremities in 9.8% of the patients. The histopathologic subtypes were embryonal in 80.4%, alveolar in 9.8%, and undifferentiated in 9.8%. The majority of the patients were considered group III (47%) and group IV (25.5%) according the criteria of the Intergroup Rhabdomyosarcoma Study (IRS). Primary total tumour resection was performed in only 27.5% of the patients. The patients were treated with assigned regimens of IRS II and IRS III protocols. Radiotherapy was applied to 92.1% of the patients. Thirty-four patients (66.7%) were lost to follow up, and of the remaining 17 patients, 7 patients (41.2%) died, relapse occurred in 9 patients (52.9%) and 10 patients (58.8%) are alive. The percentage of cases lost to follow up during the first 10 years and the following 9 years of the study were 77.4% and 50%, respectively. Incompliance with cancer treatment remains a major problem in developing countries.